thebiostories

Phase 1 Clinical Trials of MK-7602: A Promising New Chapter in the Fight Against Malaria From Laboratory Discovery to Human Trials Every new antimalarial medicine begins with a simple question: Can scientists stay ahead of one of humanity's oldest and most adaptable killers? For decades, malaria parasites have repeatedly evolved resistance to medicines that once transformed global malaria control. Each time a highly effective treatment has been introduced, the parasite has eventually found new ways to survive, creating an urgent need for drugs with entirely different mechanisms of action. In March 2026, researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI) reached an important milestone in that ongoing battle. Early clinical trial results showed that the experimental antimalarial drug MK-7602 was well tolerated in healthy volunteers and achieved blood concentrations predicted to effectively kill malaria parasites. Although Phase 1 clinical trials are d...